Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery.
OBJECTIVE
This study compared the efficacy of aminocaproic acid and tranexamic acid in reducing postoperative blood loss, as well as blood and blood product requirements in children with cyanotic congenital heart disease.


METHODS
A prospective randomized study.


METHODS
Cardiac center of a tertiary care, referral hospital.


METHODS
One hundred fifty children in the age group of 2 months to 14.5 years with cyanotic congenital heart disease undergoing corrective surgery on cardiopulmonary bypass (CPB).


METHODS
Patients were randomized into 3 groups. Group A was given aminocaproic acid in a dose of 100 mg/kg after anesthetic induction, 100 mg/kg on CPB and 100 mg/kg after protamine. Group T was given tranexamic acid, 10 mg/kg, after anesthetic induction, 10 mg/kg on CPB, and 10 mg/kg after protamine. Group C was the control group.


RESULTS
Control group had the longest sternal closure time, maximum blood loss at 24 hours, and maximum requirements of blood and blood products. Among the 2 groups given antifibrinolytics, there was no significant difference in postoperative blood loss, blood and product requirement, and reexploration rates.


CONCLUSIONS
Aminocaproic acid and tranexamic acid are equally effective in reducing postoperative blood loss, as well as blood and blood product requirements in children with cyanotic heart disease undergoing corrective surgery as compared with the control group.
Chauhan
Sandeep
S
Department of Cardiac Anesthesia, All India Institute of Medical Sciences, New Delhi, India. sdeep61@yahoo.com
Das
Sambhu N
SN
Bisoi
Akshay
A
Kale
Shailaja
S
Kiran
Usha
U
D000293:Adolescent; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D001803:Blood Transfusion / Q000379:methods; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D002648:Child; D002675:Child, Preschool; D005260:Female; D006330:Heart Defects, Congenital / Q000097:blood / Q000601:surgery; D006494:Heparin Antagonists / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011446:Prospective Studies; D011479:Protamines / Q000627:therapeutic use; D013997:Time Factors; D014148:Tranexamic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome
D000933:Antifibrinolytic Agents; D006494:Heparin Antagonists; D011479:Protamines; D014148:Tranexamic Acid; D015119:Aminocaproic Acid